Insider Selling: Cullinan Oncology, Inc. (NASDAQ:CGEM) Major Shareholder Sells 29,631 Shares of Stock

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Bioscience I. 2017 Ltd F2 sold 29,631 shares of Cullinan Oncology stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $13.00, for a total value of $385,203.00. Following the completion of the sale, the insider now owns 537,392 shares in the company, valued at $6,986,096. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

CGEM stock traded up $0.59 during trading on Thursday, hitting $13.32. The stock had a trading volume of 288,158 shares, compared to its average volume of 401,262. Cullinan Oncology, Inc. has a twelve month low of $7.30 and a twelve month high of $30.33. The stock has a market capitalization of $596.51 million, a P/E ratio of -7.53 and a beta of 0.17. The company’s 50-day moving average price is $11.14 and its two-hundred day moving average price is $12.93.

Cullinan Oncology (NASDAQ:CGEM – Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.34. As a group, equities analysts anticipate that Cullinan Oncology, Inc. will post 3.39 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Citigroup Inc. lifted its holdings in Cullinan Oncology by 265.7% in the third quarter. Citigroup Inc. now owns 3,171 shares of the company’s stock valued at $72,000 after acquiring an additional 2,304 shares during the last quarter. Dupont Capital Management Corp acquired a new position in Cullinan Oncology in the first quarter valued at approximately $119,000. MetLife Investment Management LLC lifted its holdings in Cullinan Oncology by 57.0% in the first quarter. MetLife Investment Management LLC now owns 15,398 shares of the company’s stock valued at $161,000 after acquiring an additional 5,590 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in Cullinan Oncology by 52.1% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,536 shares of the company’s stock valued at $163,000 after acquiring an additional 3,611 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Cullinan Oncology in the fourth quarter valued at approximately $166,000. Institutional investors and hedge funds own 93.62% of the company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Cullinan Oncology in a report on Tuesday, May 17th.

About Cullinan Oncology (Get Rating)

Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

See Also